SomaLogic has filed a patent for polynucleotides called aptamers, which contain modified pyrimidines at the 5-position. The patent also covers methods of selecting and using these aptamers. The aptamers consist of at least one first 5-position modified pyrimidine and at least one second 5-position modified pyrimidine, with the first and second pyrimidines being different. The patent specifies various combinations of modified pyrimidines that can be used in the aptamers. GlobalData’s report on SomaLogic gives a 360-degree view of the company including its patenting strategy. Buy the report here.
According to GlobalData’s company profile on SomaLogic, molecular diagnosis biomarkers was a key innovation area identified from patents. SomaLogic's grant share as of September 2023 was 45%. Grant share is based on the ratio of number of grants to total number of patents.
The patent is filed for polynucleotides (aptamers) with modified pyrimidines
A recently filed patent (Publication Number: US20230313202A1) describes an aptamer that includes modified pyrimidines at the 5-position. The aptamer consists of at least one first 5-position modified pyrimidine and at least one second 5-position modified pyrimidine, with the two modified pyrimidines being different. The first modified pyrimidine can be a 5-position modified uridine, while the second modified pyrimidine can be a 5-position modified cytidine, or vice versa. Various combinations of modified pyrimidines are mentioned, including PPdC and TyrdU, PPdC and PPdU, PPdC and NapdU, PPdC and ThrdU, NapdC and NapdU, NapdC and PPdU, NapdC and ThrdU, and NapdC and MOEdU.
The patent also describes a composition comprising multiple polynucleotides, each containing the same combination of modified pyrimidines as the aptamer. The polynucleotides can have a fixed region at the 5' and/or 3' end, with the length of the fixed region ranging from at least 10 nucleotides to at least 30 nucleotides. Additionally, the composition can include a random region.
Furthermore, the patent discloses methods for using the aptamer and composition. These methods involve detecting the presence or absence of a target molecule in a sample by incubating the aptamer or composition with the sample and then detecting the aptamer, aptamer-target complex, or target molecule. The sample can be various biological fluids or tissues, such as blood, urine, saliva, or tissue biopsies.
The patent also describes a method for identifying aptamers that can bind to a target molecule. This method involves contacting a library of aptamers with the target molecule, partitioning the aptamer-target complex, dissociating the complex, and identifying the aptamers capable of binding to the target molecule.
One notable claim in the patent is that the aptamer described has improved nuclease stability and a longer half-life in human serum compared to an aptamer with unmodified pyrimidines. This claim suggests that the modified pyrimidines may enhance the stability and effectiveness of the aptamer in various applications.
Overall, this patent provides detailed information about the design, composition, and methods of using aptamers with modified pyrimidines, potentially opening up new possibilities for diagnostic and therapeutic applications.